Background: Patients in the intensive care unit (ICU) often experience poor sleep quality. Pharmacologic sleep aids are frequently used as primary or adjunctive therapy to improve sleep, although their benefits in the ICU remain uncertain. This review aims to provide a comprehensive assessment of the objective and subjective effects of medications used for sleep in the ICU, as well as their adverse effects. Methods: PubMed, Web of Science, Scopus, Embase, and Cochrane Central Register of Controlled Trials were systematically searched from their inception until June 2023 for comparative studies assessing the effects of pharmacologic sleep aids on objective and subjective metrics of sleep. Results: Thirty-four studies with 3498 participants were included. Medications evaluated were melatonin, ramelteon, suvorexant, propofol, and dexmedetomidine. The majority of studies were randomized controlled trials. Melatonin and dexmedetomidine were the best studied agents. Objective sleep metrics included polysomnography (PSG), electroencephalography (EEG), bispectral index, and actigraphy. Subjective outcome measures included patient questionnaires and nursing observations. Evidence for melatonin as a sleep aid in the ICU was mixed but largely not supportive for improving sleep. Evidence for ramelteon, suvorexant, and propofol was too limited to offer definitive recommendations. Both objective and subjective data supported dexmedetomidine as an effective sleep aid in the ICU, with PSG/EEG in 303 ICU patients demonstrating increased sleep duration and efficiency, decreased arousal index, decreased percentage of stage N1 sleep, and increased absolute and percentage of stage N2 sleep. Mild bradycardia and hypotension were reported as side effects of dexmedetomidine, whereas the other medications were reported to be safe. Several ongoing studies have not yet been published, mostly on melatonin and dexmedetomidine. Conclusions: While definitive conclusions cannot be made for most medications, dexmedetomidine improved sleep quantity and quality in the ICU. These benefits need to be balanced with possible hemodynamic side effects.
DevlinJWSkrobikYGélinasC, et al.Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825–e873.
2.
BarrJFraserGLPuntilloK, et al.Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
3.
GaborJYCooperABHanlyPJ. Sleep disruption in the intensive care unit. Curr Opin Crit Care. 2001;7(1):21–27.
4.
ParthasarathySTobinMJ. Sleep in the intensive care unit. Intensive Care Med. 2004;30(2):197–206.
5.
FrieseRS. Sleep and recovery from critical illness and injury: a review of theory, current practice, and future directions. Crit Care Med. 2008;36(3):697–705.
6.
Figueroa-RamosMIArroyo-NovoaCMLeeKAPadillaGPuntilloKA. Sleep and delirium in ICU patients: a review of mechanisms and manifestations. Intensive Care Med. 2009;35(5):781–795.
7.
WeinhouseGLWatsonPL. Sedation and sleep disturbances in the ICU. Anesthesiol Clin. 2011;29(4):675–685.
8.
KamdarBBNeedhamDMCollopNA. Sleep deprivation in critical illness: its role in physical and psychological recovery. J Intensive Care Med. 2012;27(2):97–111.
9.
DelaneyLJVan HarenFLopezV. Sleeping on a problem: the impact of sleep disturbance on intensive care patients—a clinical review. Ann Intensive Care. 2015;5(3):1–10.
10.
PisaniMAFrieseRSGehlbachBKSchwabRJWeinhouseGLJonesSF. Sleep in the intensive care unit. Am J Respir Crit Care Med. 2015;191(7):731–738.
11.
KnauertMPGilmoreEJMurphyTE, et al.Association between death and loss of stage N2 sleep features among critically Ill patients with delirium. J Crit Care. 2018;48:124–129.
12.
HonarmandKRafayHLeJ, et al.A systematic review of risk factors for sleep disruption in critically ill adults. Crit Care Med. 2020;48(7):1066–1074.
13.
FreedmanNSKotzerNSchwabRJ. Patient perception of sleep quality and etiology of sleep disruption in the intensive care unit. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1155–1162.
14.
LittleAEthierCAyasNThanachayanontTJiangDMehtaS. A patient survey of sleep quality in the intensive care unit. Minerva Anestesiol. 2012;78(4):406–414.
15.
TemboACParkerVHigginsI. The experience of sleep deprivation in intensive care patients: findings from a larger hermeneutic phenomenological study. Intensive Crit Care Nurs. 2013;29(6):310–316.
16.
AltmanMTKnauertMPPisaniMA. Sleep disturbance after hospitalization and critical illness: a systematic review. Ann Am Thorac Soc. 2017;14(9):1457–1468.
17.
FreedmanNSGazendamJLevanLPackAISchwabRJ. Abnormal sleep/wake cycles and the effect of environmental noise on sleep disruption in the intensive care unit. Am J Respir Crit Care Med. 2001;163(2):451–457.
18.
FrieseRSDiaz-ArrastiaRMcBrideDFrankelHGentilelloLM. Quantity and quality of sleep in the surgical intensive care unit: are our patients sleeping?J Trauma. 2007;63(6):1210–1214.
19.
ElliottRMcKinleySCistulliPFienM. Characterisation of sleep in intensive care using 24-hour polysomnography: an observational study. Crit Care. 2013;17(2):R46.
20.
KnauertMPHaspelJAPisaniMA. Sleep loss and circadian rhythm disruption in the intensive care unit. Clin Chest Med. 2015;36(3):419–429.
21.
PisaniMAD'AmbrosioC. Sleep and delirium in adults who are critically ill: a contemporary review. Chest. 2020;157(4):977–984.
22.
WaydhasCDeffnerTGaschlerR, et al.Sedation, sleep-promotion, and non-verbal and verbal communication techniques in critically ill intubated or tracheostomized patients: results of a survey. BMC Anesthesiol. 2022;22(1):384.
23.
HuRFJiangXYChenJ, et al.Non-pharmacological interventions for sleep promotion in the intensive care unit. Cochrane Database Syst Rev. 2015;2015(10):Cd008808.
24.
HamidiARobertsRJWeinhouseGL, et al.Characterization of nocturnal neuroactive medication use and related sleep documentation in critically ill adults. Crit Care Explor. 2021;3(3):e0367.
25.
WongCHoJAnkravsMJ, et al.Administration of pharmacological sleep aids prior to, during and following critical illness. Intern Med J. 2022;52(11):1962–1970.
26.
DevlinJWRobertsRJ. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Crit Care Clin. 2009;25(3):431–449, vii.
27.
MulkeyMAEverhartDE. Sedation selection to reduce delirium risk: why dexmedetomidine may be a better choice. J Am Assoc Nurse Pract. 2020;33(4):266–270.
28.
ChangYHuangYTChiKYHuangYT. Remimazolam versus propofol for procedural sedation: a meta-analysis of randomized controlled trials. PeerJ. 2023;11:e15495.
29.
KokLSlooterAJHillegersMHvan DijkDVeldhuijzenDS. Benzodiazepine use and neuropsychiatric outcomes in the ICU: a systematic review. Crit Care Med. 2018;46(10):1673–1680.
30.
de MendonçaFMRde MendonçaGSouzaLC, et al.Benzodiazepines and sleep architecture: a systematic review. CNS Neurol Disord Drug Targets. 2023;22(2):172–179.
31.
SateiaMJBuysseDJKrystalADNeubauerDNHealdJL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–349.
32.
RiemannDBaglioniCBassettiC, et al.European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675–700.
33.
SørensenKMOlesenCMeyhoffCSAndersenLPK. The use of melatonin in Danish intensive care departments—a nationwide observational study. Acta Anaesthesiol Scand. 2022;66(7):833–837.
34.
DaouMTeliasIYounesMBrochardLWilcoxME. Abnormal sleep, circadian rhythm disruption, and delirium in the ICU: are they related?Front Neurol. 2020;11:549908.
35.
MatsuokaASogawaRMurakawa-HirachiT, et al.Evaluation of the delirium preventive effect of dual orexin receptor antagonist (DORA) in critically ill adult patients requiring ventilation with tracheal intubation at an advanced emergency center: a single-center, retrospective, observational study. Gen Hosp Psychiatry. 2023;83:123–129.
36.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J.2021;372:n71.
37.
SterneJACSavovićJPageMJ, et al.Rob 2: a revised tool for assessing risk of bias in randomised trials. Br Med J.2019;366:l4898.
38.
ShiloLDaganYSmorjikY, et al.Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiol Int. 2000;17(1):71–76.
39.
IbrahimMGBellomoRHartGK, et al.A double-blind placebo-controlled randomised pilot study of nocturnal melatonin in tracheostomised patients. Crit Care Resusc. 2006;8(3):187–191.
40.
BourneRSMillsGHMinelliC. Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit Care. 2008;12(2):R52.
41.
ForemanBWestwoodAJClaassenJBazilCW. Sleep in the neurological intensive care unit: feasibility of quantifying sleep after melatonin supplementation with environmental light and noise reduction. J Clin Neurophysiol. 2015;32(1):66–74.
42.
MistralettiGUmbrelloMSabbatiniG, et al.Melatonin reduces the need for sedation in ICU patients: a randomized controlled trial. Minerva Anestesiol.2015;81(12):1298–1310.
43.
BellapartJAppaduraiVLassig-SmithMStuartJZappalaCBootsR. Effect of exogenous melatonin administration in critically ill patients on delirium and sleep: a randomized controlled trial. Crit Care Res Pract. 2020;2020:3951828.
44.
GandolfiJVDi BernardoAPAChanesDAV, et al.The effects of melatonin supplementation on sleep quality and assessment of the Serum melatonin in ICU patients: a randomized controlled trial. Crit Care Med. 2020;48(12):e1286–e1293.
45.
KanarskiiMNekrasovaJPradhanP, et al.The high-dose of exogenous melatonin did not alter the sleep-wake cycle in anoxic brain injury patients. Sleep Med Res.2022;13(2):112–117.
46.
MousaviSAHeydariKMehravaranH, et al.Melatonin effects on sleep quality and outcomes of COVID-19 patients: an open-label, randomized, controlled trial. J Med Virol. 2022;94(1):263–271.
47.
WibrowBMartinezFEMyersE, et al.Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial. Intensive Care Med.2022;48(4):414–425.
48.
HattaKKishiYWadaK, et al.Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014;71(4):397–403.
49.
NishikimiMNumaguchiATakahashiK, et al.Effect of administration of ramelteon, a melatonin receptor agonist, on the duration of stay in the ICU: a single-center randomized placebo-controlled trial. Crit Care Med. 2018;46(7):1099–1105.
50.
JaiswalSJBagsicSRSTakataEKamdarBBAncoli-IsraelSOwensRL. Actigraphy-based sleep and activity measurements in intensive care unit patients randomized to ramelteon or placebo for delirium prevention. Sci Rep. 2023;13(1):1450.
51.
HattaKKishiYWadaK, et al.Preventive effects of suvorexant on delirium: a randomized placebo-controlled trial. J Clin Psychiatry. 2017;78(8):e970–e979.
52.
Treggiari-VenziMBorgeatAFuchs-BuderTGachoudJPSuterPM. Overnight sedation with midazolam or propofol in the ICU: effects on sleep quality, anxiety and depression. Intensive Care Med. 1996;22(11):1186–1190.
53.
KoWJHwangSLLinFYWangSSTsaiCHChuSH. Postoperative short-term sedation with propofol in cardiac surgery. J Formos Med Assoc. 1999;98(8):556–561.
54.
KondiliEAlexopoulouCXirouchakiNGeorgopoulosD. Effects of propofol on sleep quality in mechanically ventilated critically ill patients: a physiological study. Intensive Care Med. 2012;38(10):1640–1646.
55.
EngelmannCWallenbornJOlthoffDKaisersUXRüffertH. Propofol versus flunitrazepam for inducing and maintaining sleep in postoperative ICU patients. Indian J Crit Care Med. 2014;18(4):212–219.
56.
JeanRShahPYudelevichE, et al.Effects of deep sedation on sleep in critically ill medical patients on mechanical ventilation. J Sleep Res. 2020;29(3):e12894.
57.
AlexopoulouCKondiliEDiamantakiE, et al.Effects of dexmedetomidine on sleep quality in critically ill patients: a pilot study. Anesthesiology. 2014;121(4):801–807.
58.
SuXMengZTWuXH, et al.Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet. 2016;388(10054):1893–1902.
59.
WuXHCuiFZhangC, et al.Low-dose dexmedetomidine improves sleep quality pattern in elderly patients after noncardiac surgery in the intensive care unit: a pilot randomized controlled trial. Anesthesiology. 2016;125(5):979–991.
60.
LuWFuQLuoXFuSHuK. Effects of dexmedetomidine on sleep quality of patients after surgery without mechanical ventilation in ICU. Medicine (Baltimore). 2017;96(23):e7081.
61.
SkrobikYDupreyMSHillNSDevlinJW. Low-dose nocturnal dexmedetomidine prevents ICU delirium. A randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2018;197(9):1147–1156.
62.
RomagnoliSVillaGFontanarosaL, et al.Sleep duration and architecture in non-intubated intensive care unit patients: an observational study. Sleep Med. 2020;70:79–87.
63.
HeXChengKMDuanYQ, et al.Feasibility of low-dose dexmedetomidine for prevention of postoperative delirium after intracranial operations: a pilot randomized controlled trial. BMC Neurol.2021;21(1):12.
64.
SunYMZhuSNZhangCLiSLWangDX. Effect of low-dose dexmedetomidine on sleep quality in postoperative patients with mechanical ventilation in the intensive care unit: a pilot randomized trial. Front Med (Lausanne). 2022;9:931084.
65.
UenoYSatoKMomotaK, et al.The quality and quantity of sleep on dexmedetomidine during high-flow nasal cannula oxygen therapy in critically ill patients. J Med Invest. 2022;69(3.4):266–272.
66.
HuangJQinMLuWShenX. Dexmedetomidine improved sleep quality in the intensive care unit after laryngectomy. Drug Des Devel Ther. 2023;17:1631–1640.
67.
OxlundJKnudsenTSörbergMStrømTToftPJennumPJ. Sleep quality and quantity determined by polysomnography in mechanically ventilated critically ill patients randomized to dexmedetomidine or placebo. Acta Anaesthesiol Scand. 2023;67(1):66–75.
68.
QuJZMuellerAMcKayTB, et al.Nighttime dexmedetomidine for delirium prevention in non-mechanically ventilated patients after cardiac surgery (MINDDS): a single-centre, parallel-arm, randomised, placebo-controlled superiority trial. EClinicalMedicine. 2023;56:14.
69.
CorbettSMRebuckJAGreeneCM, et al.Dexmedetomidine does not improve patient satisfaction when compared with propofol during mechanical ventilation. Crit Care Med. 2005;33(5):940–945.
70.
AlsulamiGRiceAMKiddL. Prospective repeated assessment of self-reported sleep quality and sleep disruptive factors in the intensive care unit: acceptability of daily assessment of sleep quality. BMJ Open. 2019;9(6):11.
71.
GeorgopoulosDKondiliEAlexopoulouCYounesM. Effects of sedatives on sleep architecture measured with odds ratio product in critically ill patients. Crit Care Explor. 2021;3(8):e0503.
72.
NicholsonTPatelJSleighJW. Sleep patterns in intensive care unit patients: a study using the bispectral index. Crit Care Resusc. 2001;3(2):86–91.
73.
BourneRSMinelliCMillsGHKandlerR. Clinical review: sleep measurement in critical care patients: research and clinical implications. Crit Care. 2007;11(4):226.
74.
BenissaMRKhiraniSHartleyS, et al.Utility of the bispectral index for assessing natural physiological sleep stages in children and young adults. J Clin Monit Comput. 2016;30(6):957–963.
75.
RichardsKCWangYYJunJYeL. A systematic review of sleep measurement in critically ill patients. Front Neurol. 2020;11:542529.
76.
Ancoli-IsraelSColeRAlessiCChambersMMoorcroftWPollakCP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003;26(3):342–392.
77.
RichardsKCO'SullivanPSPhillipsRL. Measurement of sleep in critically ill patients. J Nurs Meas. 2000;8(2):131–144.
78.
KamdarBBShahPAKingLM, et al.Patient-nurse interrater reliability and agreement of the Richards-Campbell Sleep Questionnaire. Am J Crit Care. 2012;21(4):261–269.
79.
ParrottACHindmarchI. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations—a review. Psychopharmacology (Berl). 1980;71(2):173–179.
80.
RoodPFrenzelTVerhageR, et al.Development and daily use of a numeric rating score to assess sleep quality in ICU patients. J Crit Care. 2019;52:68–74.
81.
MoYScheerCEAbdallahGT. Emerging role of melatonin and melatonin receptor agonists in sleep and delirium in intensive care unit patients. J Intensive Care Med. 2016;31(7):451–455.
82.
TordjmanSChokronSDelormeR, et al.Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15(3):434–443.
83.
MundiglerGDelle-KarthGKorenyM, et al.Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med. 2002;30(3):536–540.
84.
OlofssonKAllingCLundbergDMalmrosC. Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients. Acta Anaesthesiol Scand. 2004;48(6):679–684.
85.
YoshitakaSEgiMMorimatsuHKanazawaTTodaYMoritaK. Perioperative plasma melatonin concentration in postoperative critically ill patients: its association with delirium. J Crit Care. 2013;28(3):236–242.
86.
JobanputraAMScharfMTAndroulakisIPSunderramJ. Circadian disruption in critical illness. Front Neurol. 2020;11:820.
87.
ErlandLASaxenaPK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–281.
88.
NeubauerDN. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatr Dis Treat. 2008;4(1):69–79.
89.
MiyamotoM. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009;15(1):32–51.
90.
KuriyamaAHondaMHayashinoY. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15(4):385–392.
91.
MichelsonDSnyderEParadisE, et al.Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–471.
92.
SnyderEMaJSvetnikV, et al.Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med. 2016;19:93–100.
93.
JantoKPrichardJRPusalavidyasagarS. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018;14(8):1399–1408.
94.
HerringWJConnorKMSnyderE, et al.Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data. Sleep Med. 2019;56:219–223.
95.
GerlachATMurphyCVDastaJF. An updated focused review of dexmedetomidine in adults. Ann Pharmacother. 2009;43(12):2064–2074.
96.
TanJAHoKM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med. 2010;36(6):926–939.
97.
WeerinkMASStruysMHannivoortLNBarendsCRMAbsalomARColinP. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913.
98.
ShehabiYHoweBDBellomoR, et al.Early sedation with dexmedetomidine in critically ill patients. N Engl J Med. 2019;380(26):2506–2517.
99.
AkejuOBrownEN. Neural oscillations demonstrate that general anesthesia and sedative states are neurophysiologically distinct from sleep. Curr Opin Neurobiol. 2017;44:178–185.
100.
AkejuOHobbsLEGaoL, et al.Dexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans: a pilot study. Clin Neurophysiol. 2018;129(1):69–78.
101.
RamaswamySMWeerinkMASStruysMNagarajSB. Dexmedetomidine-induced deep sedation mimics non-rapid eye movement stage 3 sleep: large-scale validation using machine learning. Sleep. 2021;44(2):1–11.
102.
HeavnerMSLouzonPRGormanEFLandolfKMVenturaDDevlinJW. A rapid systematic review of pharmacologic sleep promotion modalities in the intensive care unit. J Intensive Care Med. 2023;39(1):28–43.
103.
RichardsKNagelCMarkieMElwellJBaroneC. Use of complementary and alternative therapies to promote sleep in critically ill patients. Crit Care Nurs Clin North Am. 2003;15(3):329–340.
104.
BourneRSMillsGH. Sleep disruption in critically ill patients—pharmacological considerations. Anaesthesia. 2004;59(4):374–384.
105.
BourneRSMillsGH. Melatonin: possible implications for the postoperative and critically ill patient. Intensive Care Med. 2006;32(3):371–379.
106.
BellapartJBootsR. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth. 2012;108(4):572–580.
107.
KurdiMSPatelT. The role of melatonin in anaesthesia and critical care. Indian J Anaesth. 2013;57(2):137–144.
108.
KanjiSMeraAHuttonB, et al.Pharmacological interventions to improve sleep in hospitalised adults: a systematic review. BMJ Open. 2016;6(7):e012108.
109.
LewisSRPritchardMWSchofield-RobinsonOJAldersonPSmithAF. Melatonin for the promotion of sleep in adults in the intensive care unit. Cochrane Database Syst Rev. 2018;5(5):Cd012455.
110.
MarraAMcGraneTJHensonCPPandharipandePP. Melatonin in critical care. Crit Care Clin. 2019;35(2):329–340.
111.
SmithburgerPLPatelMK. Pharmacologic considerations surrounding sedation, delirium, and sleep in critically Ill adults: a narrative review. J Pharm Pract. 2019;32(3):271–291.
112.
ZhangQYGaoFQZhangSSunWLiZR. Prophylactic use of exogenous melatonin and melatonin receptor agonists to improve sleep and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials. Sleep Breath. 2019;23(4):1059–1070.
113.
BritoRAdo Nascimento Rebouças VianaSMBeltrãoBAde Araújo MagalhãesCBde BruinVMSde BruinPFC. Pharmacological and non-pharmacological interventions to promote sleep in intensive care units: a critical review. Sleep Breath. 2020;24(1):25–35.
114.
CookeMRitmala-CastrénMDwanTMitchellM. Effectiveness of complementary and alternative medicine interventions for sleep quality in adult intensive care patients: a systematic review. Int J Nurs Stud. 2020;107:103582.
115.
FontaineGVDer NigoghossianCMelatoninHLRamelteonS. And dexmedetomidine to promote sleep and prevent delirium in critically ill patients: a narrative review with practical applications. Crit Care Nurs Q. 2020;43(2):232–250.
116.
LewandowskaKMałkiewiczMASiemińskiMCubałaWJWinklewskiPJMędrzycka-DąbrowskaWA. The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit—a clinical review. Sleep Med. 2020;69:127–134.
117.
RichardsGABentleyAGopalanPDBranniganLParukF. Is there a role for melatonin in the ICU?South Afr J Crit Care. 2021;37(2):77–82.
118.
HuangHWZhengBLJiangL, et al.Effect of oral melatonin and wearing earplugs and eye masks on nocturnal sleep in healthy subjects in a simulated intensive care unit environment: which might be a more promising strategy for ICU sleep deprivation?Crit Care. 2015;19(1):124.
119.
DelaneyLJLittonEMelehanKLHuangHCLopezVVan HarenF. The feasibility and reliability of actigraphy to monitor sleep in intensive care patients: an observational study. Crit Care. 2021;25(1):42.
120.
KawadaKOhtaTTanakaKMiyamuraMTanakaS. Addition of suvorexant to ramelteon therapy for improved sleep quality with reduced delirium risk in acute stroke patients. J Stroke Cerebrovasc Dis. 2019;28(1):142–148.
121.
De CrescenzoFD'AlòGLOstinelliEG, et al.Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170–184.
122.
PanBGeLLaiH, et al.The comparative effectiveness and safety of insomnia drugs: a systematic review and network meta-analysis of 153 randomized trials. Drugs. 2023;83(7):587–619.
123.
LewisSRSchofield-RobinsonOJAldersonPSmithAF. Propofol for the promotion of sleep in adults in the intensive care unit. Cochrane Database Syst Rev.2018;1(1):Cd012454.
124.
McLeodGWallisCDickJCoxCPattersonAColvinJ. Use of 2% propofol to produce diurnal sedation in critically ill patients. Intensive Care Med. 1997;23(4):428–434.
125.
RomagnoliSAmigoniABlangettiI, et al.Light sedation with dexmedetomidine: a practical approach for the intensivist in different ICU patients. Minerva Anestesiol. 2018;84(6):731–746.
126.
HuangXLinDDSunYWuASWeiCW. Effect of dexmedetomidine on postoperative sleep quality: a systematic review. Drug Des Devel Ther. 2021;15:2161–2170.
127.
WiegandABehalMRobbinsBBissellBPandyaKMeffordB. Niche roles for dexmedetomidine in the intensive care unit. Ann Pharmacother. 2023;57(10):1207–1220.
128.
OtoJYamamotoKKoikeSOnoderaMImanakaHNishimuraM. Sleep quality of mechanically ventilated patients sedated with dexmedetomidine. Intensive Care Med. 2012;38(12):1982–1989.
129.
TurunenHJakobSMRuokonenE, et al.Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation. Crit Care. 2015;19(1):67.
130.
AggarwalJLustrinoJStephensJMorgensternDTangWY. Cost-minimization analysis of dexmedetomidine compared to other sedatives for short-term sedation during mechanical ventilation in the United States. Clinicoecon Outcomes Res. 2020;12:389–397.
131.
OxlundJKnudsenTLeonthinHToftPJennumPJ. Subjective sleep assessment compared to polysomnography in mechanically ventilated critically ill ICU patients. Acta Anaesthesiol Scand. 2023;67(3):311–318.
132.
BeecroftJMWardMYounesMCrombachSSmithOHanlyPJ. Sleep monitoring in the intensive care unit: comparison of nurse assessment, actigraphy and polysomnography. Intensive Care Med. 2008;34(11):2076–2083.
133.
DrouotXRoche-CampoFThilleAW, et al.A new classification for sleep analysis in critically ill patients. Sleep Med. 2012;13(1):7–14.
134.
WatsonPLPandharipandePGehlbachBK, et al.Atypical sleep in ventilated patients: empirical electroencephalography findings and the path toward revised ICU sleep scoring criteria. Crit Care Med. 2013;41(8):1958–1967.
135.
BoykoYJennumPToftP. Sleep quality and circadian rhythm disruption in the intensive care unit: a review. Nat Sci Sleep. 2017;9:277–284.
136.
GarpestadEDevlinJW. Polypharmacy and delirium in critically ill older adults: recognition and prevention. Clin Geriatr Med. 2017;33(2):189–203.
137.
AzumaKTakaesuYSoedaH, et al.Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute Med Surg. 2018;5(4):362–368.
138.
MasuyamaTSanuiMYoshidaN, et al.Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study. Psychogeriatrics. 2018;18(3):209–215.
139.
TsunemitsuTKataokaYMatsumotoMHashimotoTSuzukiT. Effect of enterally administered sleep-promoting medication on the intravenous sedative dose and its safety and cost profile in mechanically ventilated patients: a retrospective cohort study. PLoS One. 2021;16(12):e0261305.
140.
SoltaniFSalariAJavaherforooshzadehFNassajjianNKalantariF. The effect of melatonin on reduction in the need for sedative agents and duration of mechanical ventilation in traumatic intracranial hemorrhage patients: a randomized controlled trial. Eur J Trauma Emerg Surg. 2022;48(1):545–551.
141.
SolimanMSMostafaGMElsabeenyWBadrMRadwanTAOsmanSH. The effect of melatonin administration on sedation level as adjuvant to propofol in mechanically ventilated traumatic brain injury patients. Egypt J Anaesth. 2023;39(1):19–25.
142.
PisaniMAMurphyTEAraujoKLSlattumPVan NessPHInouyeSK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med. 2009;37(1):177–183.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
